Join our Community Webinar Series on November 17 at 11AM ET while we are joined by Edgewise Therapeutics to learn more about the clinical development program for EDG-5506, a myosin modulator, in Becker and Duchenne muscular dystrophies. The presentation will highlight the mechanism of action, results from the ongoing open label ARCH study in adults with Becker muscular dystrophy, and upcoming trials.
Edgewise Therapeutics: A Novel Approach to Protect Muscle in Duchenne and Becker Muscular Dystrophy
Thursday, November 17, 2022 | 11:00AM – 12:00PM EST
Dr. Joanne M. Donovan has been Chief Medical Officer at Edgewise Therapeutics since 2021. Previously, she served as Chief Medical Officer and Senior Vice President, Clinical Development at Catabasis Pharmaceuticals, where she led clinical development in therapeutic areas including Duchenne muscular dystrophy. Since 1989, she has been a staff physician at the VA Boston Healthcare System, where she was formerly Chief of Gastroenterology. Dr. Donovan has held appointments at Harvard Medical School, currently as Associate Clinical Professor of Medicine. From 1998 to 2011, Dr. Donovan served in positions of increasing responsibility, ultimately as vice president of clinical development, at Genzyme, a biotechnology company, where she played leadership roles in programs from IND to NDA in therapeutic areas including rare disease.
Dr. Donovan holds a Ph.D. in medical engineering and medical physics from the Massachusetts Institute of Technology, an M.D. from Harvard Medical School and an S.B. from the Massachusetts Institute of Technology. She completed residency training in internal medicine and a fellowship in gastroenterology at the Brigham and Women’s Hospital.
Dr. Alan Russell serves as Edgewise Therapeutics’ Co-Founder, Chief Scientific Officer and a member of their board of directors. Previously, Dr. Russell served at GlaxoSmithKline as VP and Head of the Muscle Metabolism Discovery Performance Unit, leading a broad discovery and development effort focused on patients for whom muscle function is compromised. Prior to this, he worked at Cytokinetics Inc. and is the co-inventor of Tirasemtiv and Reldesemtiv, direct muscle sensitizers in clinical trials for Amyotrophic Lateral Sclerosis (ALS). Dr. Russell received a B.Pharm. in Pharmacy and Pharmacology and Ph.D. in Cell Biology and Gene Therapy from the University of Bath in the UK and Postdoctoral training at the Stanford University School of Medicine.
Our Community Webinar Series is focused on ensuring that our Duchenne community is better prepared for those unexpected moments, challenging medical decisions, and difficult stages when on a Duchenne journey.
No one ever expects Duchenne and there is no correct way to tackle a diagnosis, but we can always better prepare. This webinar series is an opportunity to equip yourself with more knowledge, resources, and tools for those real-life, often unanticipated, scenarios.